In the TCGA cohort, AML patients with higher BATF expression had poorer prognosis (3-year OS: 27.27% vs. 56.41%, P < 0.001) (Figure 1C), Conversely, higher EGR1 expression was linked to better prognosis (3-year OS: 46.88% vs. 18.52%, P = 0.004) in AML patients (Figure 1D). This evidence concerns the gene BATF and acute myeloid leukemia.